The appeal of 3D printed splints is easy to understand. Because each device is designed from a digital scan of the individual patient’s anatomy, it can be shaped to fit precisely while remaining far lighter than a conventional cast. The printed structure can be open and lattice-like, allowing air to circulate against the skin. That improved aeration reduces the moisture buildup and skin irritation that plague cast wearers, and it also improves hygiene around the injury. Perhaps most importantly for trauma care, an open splint leaves room for wound treatment: dressings can be changed, sutures can be inspected, and infections can be managed without cutting the device off and starting over. For patients, that can mean a dramatically more comfortable recovery and fewer return visits to the emergency department.

Yet despite these advantages, patient-specific printed splints remain rare in daily clinical practice. The reason is not that the technology does not work — small studies and prototype programs have demonstrated it repeatedly — but that getting from a working prototype to a routine hospital service is genuinely hard. The Nijmegen team, which included trauma surgeons, 3D printing specialists, and a biomechanical engineer from the University of Twente, identified three intertwined categories of difficulty. There are technical and logistical challenges, such as choosing scanners, design software, and printers that can produce medically acceptable devices reliably. There are workflow adjustments, because the path from patient to finished splint must fit into the fast-paced routines of an acute care setting. And there are regulatory constraints, because a hospital that manufactures its own medical devices steps into the role of a device producer under European medical device regulation, with all the documentation and quality obligations that entails.

To confront these barriers, the researchers did something unusually practical for an academic paper: they ran the implementation on-site, at a level-one trauma center with military affiliation in the Netherlands. Rather than designing a theoretical framework in an office, they organized multidisciplinary workshops in which the people who would actually operate the service — trauma surgeons, 3D lab staff, and other stakeholders — sat down together to identify, document, and discuss every essential obstacle they encountered. The workshops served as a structured forum for surfacing problems that might otherwise remain invisible until they caused a failure: who is responsible when a printer breaks mid-production, how a scan moves from the emergency room to the design workstation, which software licenses the hospital must hold, and how the finished device is documented for regulatory purposes.

The output of this process was a taxonomy of challenges. The team categorized the difficulties into essential barriers, each with multiple subitems, and then translated every barrier into a concrete step in a roadmap. Each step specifies the stakeholders involved and the actions required, so that a hospital following the guide knows not just what must be done but who must do it. Examples of the barriers include software and hardware selection for in-house splint production — decisions that ripple outward into training needs, maintenance contracts, and quality assurance. Other barriers concern the clinical workflow, the regulatory pathway, and the organizational changes needed to make in-house manufacturing sustainable rather than a one-off demonstration project.

The regulatory dimension deserves particular attention, because it is where many hospital innovation projects stall. Under the European Medical Device Regulation, a hospital producing custom-made devices in house is not merely using a product; it is manufacturing one. That role carries requirements for documentation, production standards, and traceability that most clinical departments have never had to meet. The roadmap addresses this by embedding the regulatory steps directly into the implementation sequence, so that quality obligations are built in from the start rather than retrofitted after problems arise. This is a significant shift from the way many hospitals have approached 3D printing, treating it as a research activity with looser obligations rather than a clinical service with strict ones.

The military affiliation of the participating hospital adds an interesting layer to the work. Military medicine has long been an early adopter of portable and on-demand manufacturing, since deployed units cannot rely on supply chains for specialized equipment. The involvement of the Military Health Organisation of the Dutch Ministry of Defence, reflected in the author affiliations, suggests that the roadmap was shaped by perspectives from both civilian trauma care and military health logistics. A hospital that can print its own splints from digital scans is also a hospital that can maintain essential capability when external suppliers are unavailable — a resilience argument that resonates well beyond the trauma ward.

To make sure the roadmap was actually usable by the people it is meant for, the researchers put the finished implementation guide in front of end-users and collected their feedback through a questionnaire. This review step is more than a courtesy; it is a check on whether the document communicates clearly to clinicians and technical staff who were not part of the workshops. The team reports that the roadmap provides a structured approach to meeting the requirements for implementation into both research and daily clinical practice — a dual purpose that matters, because many hospitals will want to run a research program first, gather evidence on safety and effectiveness, and only then transition to routine service.

For hospital administrators reading the study, the practical message is that in-house 3D printing of patient-specific splints is achievable, but only with deliberate planning across multiple domains simultaneously. The roadmap’s structure — essential barriers broken into subitems, each mapped to stakeholders and actions — gives institutions a checklist for the conversations they must have before buying a single printer. Which department owns the service? Who designs the devices, and with what software? How are scans acquired, stored, and protected? What documentation satisfies the regulator? How are staff trained, and how is the service maintained when key personnel leave? None of these questions is individually difficult, but the study’s central insight is that they must all be answered together, in a coordinated sequence, for the implementation to succeed.

The broader significance of the work lies in what it represents for hospital-based manufacturing as a whole. Splints are a relatively simple class of medical device, which makes them an ideal proving ground for the organizational machinery of in-house production. A hospital that masters the workflow, regulatory, and quality challenges of printed splints has built the institutional capability to produce other custom devices — surgical guides, prosthetic components, and beyond. The Nijmegen team’s roadmap, born from the friction of real implementation rather than from theory, offers other institutions a way to skip some of that friction. As 3D printing hardware becomes cheaper and design software more accessible, the limiting factor in bringing personalized devices to patients is increasingly not the technology but the organization around it — and that is precisely the problem this study set out to solve.

Subject of Research: In-house production of patient-specific 3D printed splints in acute care

Article Title: An implementation roadmap for in-house production of patient-specific 3D printed splints in an acute care setting

Article References: van Ginkel, L. A., de Bruijn, M. A. N., Hermans, E., Maal, T. J. J., Stirler, V. M. A., & Tuijthof, G. J. M. (2026). An implementation roadmap for in-house production of patient-specific 3D printed splints in an acute care setting. 3D Printing in Medicine. https://doi.org/10.1186/s41205-026-00343-9

Image Credits: AI Generated

DOI: 10.1186/s41205-026-00343-9

Keywords: 3D printing, patient-specific splints, trauma surgery, medical device regulation, implementation roadmap, acute care, hospital manufacturing, 3D Printing in Medicine, Radboudumc, custom medical devices, clinical workflow, immobilization

Vulvar cancer is not among the most common malignancies, but its impact on those diagnosed is profound. In the Netherlands, approximately 450 women receive the diagnosis each year, and in roughly one quarter of those cases the tumor involves the clitoris or the tissue immediately surrounding it. Because the disease is located in an area of dense nerve supply and intimate significance, surgery that saves a life can simultaneously alter a patient’s sexual function, body image, and overall quality of life in ways that standard oncological follow-up has historically done little to address. Gynecologic oncologist Mieke ten Eikelder of Radboudumc, who co-developed the new technique, describes the previous standard bluntly: when the tumor sits in or around the clitoris, surgeons sometimes have to remove part of it, and until now the wound was simply closed afterward, with little attention paid to whether orgasm would still be possible.

The new operation, described in the journal Gynecologic Oncology in a paper titled Clitoral reconstructive surgery for patients with vulvar carcinoma, was developed jointly by ten Eikelder and plastic surgeon Tim Nijhuis. Its central insight is that even after a tumor has been removed from the clitoral region, the underlying nerve bundles that carry sensory information can often be preserved and redirected. Rather than accepting the loss of the visible clitoral tip and the sensation that depends on it, the surgical team releases those nerve bundles and repositions them so that they converge to create a new clitoral tip. In effect, the sensory apparatus of the clitoris is gathered and rebuilt rather than discarded, giving the nerve fibers a physical structure through which they can once again generate sensation.

The second key element of the technique is the material used to cover and shape the reconstructed tip. The surgeons use a small graft of buccal mucosa, the moist tissue lining the inside of the cheek. This choice is deliberate and technically elegant. Buccal mucosa closely resembles the tissue found naturally around the vulva in both texture and behavior, making it far better suited to the genital environment than skin taken from elsewhere on the body. Grafts of this type integrate well, remain supple and moist, and provide a covering that mimics the original anatomy closely enough to support rather than blunt sensation. The combination of repositioned nerve bundles and a mucosal graft is what allows the reconstruction to preserve clitoral feeling rather than merely restoring a cosmetic contour.

From the patient’s perspective, one of the most remarkable aspects of the procedure is how little it adds to the existing cancer operation. The reconstruction extends the surgery by only about fifteen minutes. That is a strikingly small increment given what the procedure returns: for women whose tumors would otherwise have cost them clitoral sensation permanently, a quarter of an hour of additional operating time now stands between losing sexual function and keeping a realistic chance of regaining it. Because the reconstruction is performed in the same anesthetic episode as the tumor removal, patients do not face a second major operation, a second hospital stay, or a second period of recovery from surgery.

The early clinical results justify the enthusiasm. Among the first 23 women with vulvar cancer who underwent the reconstruction, ninety percent were able to achieve a clitoral orgasm again after surgery. Sensation typically returned between three and six months after the operation, a timeline that reflects the slow but reliable process of nerve recovery and tissue healing. The surgeons note that the recovery curve is not linear in its early phase. Initially, the reconstructed clitoris may be overly sensitive, or conversely less sensitive than before, but recovery is generally optimal after one year. In most women, sensation ultimately returns to a level comparable to what it was before the cancer surgery, an outcome that would have been considered unattainable only a few years ago.

The forty-year lag between penile and clitoral reconstruction is itself a point the Dutch team makes explicitly, and it speaks to a broader pattern in surgical history. Procedures that restore urinary and sexual function in men were developed, standardized, and taught in training programs long before equivalent attention was paid to female genital reconstruction beyond purely cosmetic or urinary aims. Part of the explanation lies in surgical anatomy: the penis offers a longer structure with accessible nerve and vessel pedicles that lend themselves to tubed flaps, while the clitoris is small, densely innervated, and technically demanding to rebuild in miniature. Part of the explanation, however, lies in how seriously medicine has historically taken female sexual function as an outcome worth measuring and treating. The Radboudumc work signals a shift in that regard, treating orgasm and genital sensation as legitimate reconstructive goals on par with continence or limb function.

The implications extend beyond cancer care. The researchers point out that the same reconstructive principle, repositioning preserved nerve bundles to create a functional clitoral tip and covering it with buccal mucosa, may also help women who have suffered genital mutilation. In those cases, as in cancer surgery, the sensory nerves often remain even when the external anatomy has been removed or altered, and a technique designed to gather those nerves into a new structure could offer a path to restored sensation for a population that has almost never been offered surgical options. While the published experience so far concerns women treated for vulvar carcinoma, the potential application to female genital mutilation gives the technique a reach that could eventually touch millions of women worldwide.

The procedure is now being introduced across the Netherlands as part of a structured scientific research program rather than as an uncontrolled spread of a new operation. Alongside Radboudumc, eight other Dutch hospitals treat vulvar cancer, and all of them are participating in a follow-up project in which gynecologic oncologists and plastic surgeons will be trained in the new technique. Nijhuis and ten Eikelder are also currently training specialists from other countries, an early sign that the developers intend the method to become an international standard rather than the specialty of a single center. This training-first approach reflects a growing consensus in surgical innovation that a new operation is only as good as its dissemination, and that early standardization protects patients from poorly executed imitations.

For all the promise, the researchers themselves are careful about the limits of the current evidence. The initial series of 23 patients is small, and the ninety percent figure, while remarkable, comes from early follow-up rather than long-term study. With financial support from the Dutch Cancer Society, the team will work together with other Dutch hospitals to determine whether the reconstruction truly improves sexual function and quality of life in a rigorous, multicenter evaluation, and how the technique can be safely integrated into everyday clinical care. Those studies will need to confirm that the sensory gains persist over years, that the reconstructed tissue remains healthy over the long term, and that the procedure can be reproduced reliably by surgeons trained outside the originating center. Even with those caveats, the direction of travel is clear. An operation that did not exist a few years ago has given the first group of patients back a dimension of their lives that cancer surgery had taken away, and it has done so with a fifteen-minute addition to the procedure they needed anyway. Forty years after the first penile reconstruction, the surgical playbook has finally caught up, and the women who come after these first 23 patients will enter vulvar cancer treatment knowing that survival and sexual function no longer have to be an either-or choice.

Subject of Research: Clitoral reconstructive surgery for patients with vulvar carcinoma

Article Title: New surgical technique restores the clitoris after treatment for vulvar cancer

Article References: New surgical technique restores the clitoris after treatment for vulvar cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: vulvar cancer, clitoral reconstruction, gynecologic oncology, plastic surgery, sexual function, nerve repositioning, buccal mucosa graft, Radboudumc, organ preservation, reconstructive surgery, quality of life, surgical